The third and final safety review of Part A of a Phase 1/2a clinical evaluating VBI Vaccines' (NASDAQ:VBIV) VBI-1901 in patients with recurrent glioblastoma (GBM) has been completed and the study will continue as planned without modification.
Part B, an extension of the optimal dose identified in Part A, will enroll up to 10 additional patients.
Immunological and survival data from all three cohorts in Part A should be available next quarter.
VBI-1901, administered via intradermal injection, is an immunotherapy targeting cytomegalovirus (CMV) antigens gB and pp65. CMV infection is believed to be prevalent in a range of solid tumors so an anti-CMV dendritic cell vaccination regimen may extend overall survival in GBM patients.
Shares are up 3% premarket on light volume.
Subscribe for full text news in your inbox